Dr. Cornelius Pompe joined Leukocare as Vice President R&D; Dr. Sabine Hauck appointed as Senior Vice President Corporate Development
Martinsried/Munich, Germany, August 11, 2021
Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, today announced that Dr. Cornelius Pompe joined the company as Vice President R&D. In this role, he succeeded Dr. Sabine Hauck, who has been appointed as Senior Vice President Corporate Development at Leukocare.
Michael Scholl, Chief Executive Officer at Leukocare, said, “I am delighted to welcome Cornelius to the management team. His extensive industry experience will help us to further strengthen our R&D expertise and to serve our clients in the best possible way. Moreover, I am extremely happy to have Sabine taking over as Senior VP Corporate Development. In her new position, she will play a decisive role in further driving Leukocare’s strategy to meet our customers’ needs at the best. “
Dr. Cornelius Pompe brings more than 15 years of experience in early and late stage biopharmaceutical development. Before joining Leukocare, Cornelius served as Head of Drug Product Development, Early Operations Lead and Member of the Process Development Senior Leadership Team at Amgen Research in Munich, Germany. Prior to his roles at Amgen, he held several positions in the area of drug product development at LFB Group, Courtaboeuf, France, and at Coriolis Pharma, Martinsried, Germany. Cornelius holds a PhD in Pharmaceutical Technology from Ludwig Maximilians University Munich, Germany.
Dr. Cornelius Pompe, Vice President R&D at Leukocare, commented, “I am very happy to join Leukocare´s management team. When I learned about Leukocare’s approach to combine bioinformatics and deep learning with best-in-class analytics to redefine formulation development, I was excited. In my past roles, I have experienced many challenges with formulations of complex biologics and I see a tremendous value in Leukocare’s enhanced way of making use of the full potential of a drug substance. I am convinced that Leukocare is the right place to bring in my industry experience. I am looking forward to closely collaborate with this dedicated team of experts.”
Dr. Sabine Hauck headed the R&D department at Leukocare for the last four years. In her new role as Senior Vice President Corporate Development, Sabine is responsible for aligning strategic and technical goals to provide customers with tailor-made solutions in the field of drug product formulation development for biopharmaceuticals. Sabine has 20 years of drug product development expertise as well as several years of in vitro diagnostic and biosensor development. Before joining Leukocare, Sabine was heading Pharmaceutical Development, Quality Assurance and Regulatory Affairs departments at Medigene AG, Martinsried, Germany, Acino International AG, Zurich, Switzerland and IDEA Pharma AG, Basel, Switzerland and Munich, Germany. She holds a Dr. rer. nat. from University of Regensburg, Germany.
Dr. Sabine Hauck, Senior Vice President Corporate Development at Leukocare, said, “It is a great pleasure to take up the role as Senior VP Corporate Development. Since the time I joined Leukocare in 2017, my goal has always been to support the company´s development not only in terms of R&D but also on a strategic level. Thus, I am delighted to be in a position to make a decisive contribution to Leukocare´s corporate development. “
About Leukocare AG
Leukocare AG, located in Martinsried/Munich, Germany and Milford, MA, USA, is a biotechnology company specialized in the field of biopharmaceutical formulation development. Operating at the interface of drug substance and drug product development, Leukocare combines sound knowledge of formulation development with bioinformatics and artificial intelligence.
The formulation development approach consists of two elements: a library of up to 100 different regulatory well-established and employed excipients and a rational development approach which employs statistical software and self-learning algorithms as well as state of the art design of experiment (DoE) matrices. By utilizing the artificial intelligence elements, Leukocare is able to specifically combine excipients leading to stabilizing formulations tailored to the drug product’s needs.
Leukocare’s superior and innovative drug product formulations can be applied to a broad range of applications: biologics & biosimilars, vaccines & viral vectors and biofunctionalized devices.
| Contact: | |
|---|---|
| Michael Scholl CEO michael.scholl@leukocare.com +49 (0) 89 7801 6650 |
Rebekka Ströver Specialist Communications & Marketing rebekka.stroever@leukocare.com + 49 (0) 89 7801 665 14 |